A phase I trial (NCT00729664) with 17 ovarian cancer patients treated with a PD-L1 blocking antibody (BMS-936559) resulted in a partial response in one patient and disease stabilization in two others. The gene discussed is CD274; the disease is ovarian carcinoma.